Best Undervalued Stocks To Buy For 2017


Insys Therapeutics (NASDAQ:INSY) has been bombarded with negative headlines over the last few months. Most of these stories focus on the past, what former employees did, etc. They have no bearing on the firm’s asset value or ability to generate profits in the future. As a result, Insys stock has become undervalued, and this is a good entry point

I believe this stock is the single best way for investors to bet on the growing medical cannabis industry. Insys Therapeutics offers fantastic value, based on its robust pipeline that makes growth look inevitable.


This company is the best option for those who believe in the efficacy of medical marijuana and don’t want to wait years to get returns on their investment.

Intellectual Properties

Before we look at the pipeline, let’s look at Subsys – Insys’s flagship asset. Subsys is a fentanyl nasal spray used to treat breakthrough pain in cancer patients tolerant to regular opioids. The drug captures a 48% m arket share and has the competitive advantage of faster onset and efficacy.

Best Undervalued Stocks To Buy For 2017: Kalytera Therapeutics, Inc. (QUEZF)


Advisors’ Opinion:

  • [By Javier Hasse]

    Kalytera Therapeutics Inc (OTC: QUEZF) closed a C$13.4 million ($10.2 million) tranche of a private placement for the acquisition of Talent Biotechs Ltd.

Best Undervalued Stocks To Buy For 2017: BioAmber Inc.(BIOA)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    While companies with lower-priced shares are often riskier than those with higher prices, some companies trading under $5 per share have intriguing potential. Investors searching for overlooked growth opportunities should consider industrial biotech BioAmber (NYSE:BIOA), pharmaceutical services company Codexis (NASDAQ:CDXS), and one-trick-pony biopharma Keryx Biopharmaceuticals (NASDAQ:KERX).

  • [By Lisa Levin]

    Bioamber Inc (NYSE: BIOA) shares dropped 19 percent to $2.55. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.

  • [By Markus Aarnio]

    BioAmber (BIOA) is a sustainable chemicals company. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products.

Best Undervalued Stocks To Buy For 2017: GAIN Capital Holdings, Inc.(GCAP)


Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, financial shares fell 0.16 percent. Meanwhile, top losers in the sector included Federated National Holding Co (NASDAQ: FNHC), down 11 percent, and Gain Capital Holdings Inc (NYSE: GCAP), down 7 percent.

  • [By Lisa Levin]

    FXCM Inc (NASDAQ: FXCM) shares dropped 53 percent to $3.24 after the company announced regulatory settlements with NFA and CFTC against its U.S. subsidiary, Forex Capital Markets LLC. Gain Capital Holdings Inc (NYSE: GCAP) agreed to acquire the client base of FXCM's U.S. operations after FXCM reported that it will be withdrawing from U.S. business.

Leave a Reply

Your email address will not be published. Required fields are marked *